Spectrum said with the approval of removing bioscan, patients undergoing treatment with Zevalin will now receive two infusions of rituximab, followed by a 10-minute injection of Zevalin (RRZ).
Zevalin (ibritumomab tiuxetan) intravenous injection is used to treat patients with previously untreated follicular non-Hodgkin Lymphoma (NHL).
Spectrum Pharmaceuticals MD chairman, CEO and president Rajesh Shrotriya said with this approval, they believe that physicians, patients and payers will find Zevalin to be an exceedingly more attractive treatment option.